Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA (NCT06573905)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this observational study is to validate medico-administrative algorithms that classify diabetes phenotypes (Type 1, Type 2, and Latent Autoimmune Diabetes in Adults - LADA) in a population-based cohort in Quebec, including children, adolescents, and young adults up to 40 years old with diagnosed diabetes. The main questions it aims to answer are: Can these algorithms accurately distinguish between Type 1, Type 2, and LADA across different age groups? What is the prevalence and incidence of each diabetes phenotype in Quebec? Participants will have their medical and administrative data analyzed, including data on medication usage and healthcare visits, to validate the accuracy of the algorithms. The study will involve comparing these algorithm-based classifications with clinical diagnoses or self-reported data to ensure reliability.
Who can join: Review the eligibility criteria below.
Location: Philippe Corsenac — Montreal, Quebec
Age range: 1 Year to 40 Years
🧪 Interventions in This Study
- no intervention (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Philippe Corsenac — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (438) 493-4299
Email: philippe.corsenac@uqo.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
- Allogenic Islet Cell Transplantation — Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.